Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy Pembrolizumab
Indication/Tumor Type gastroesophageal junction adenocarcinoma
Response Type sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive gastroesophageal junction adenocarcinoma sensitive Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >=1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). detail... detail... detail... 29543932
CD274 positive gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; 35914639 detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Phase I Actionable In a Phase Ib tiral, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric and gastroesophageal junction adenocarcinoma (PMID: 27157491). 27157491
PubMed Id Reference Title Details
(27157491) Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Full reference...
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. Full reference...
(29543932) Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. Full reference...
ESMO Clinical Practice Guidelines Full reference...
Full reference...
Keytruda (pembrolizumab) FDA Drug Label Full reference...
(35914639) Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Full reference...